In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis buys Corthera for $120mm plus $500mm in earn-outs

Executive Summary

Novartis has agreed to buy closely held Corthera (developing acute care therapeutics) for $120mm. Novartis will also pay Corthera shareholders earn-outs of up to $500mm for reaching clinical milestones, regulatory approval of Phase III recombinant human peptide relaxin for acute decompensated heart failure (ADHF), and hitting commercialization targets.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies